Saltikva®, provides patients and oncologists with a novel immunotherapeutic option that has been shown to be highly effective and exceptionally safe. Orally bioavailable Saltikva®, when administered ...
Salspera has set out plans for a $91 million IPO to fund the phase 3 study of its bacteria-based cancer therapy. The Cambridge, Massachusetts-based biotech is hoping to offer 5.6 million shares priced ...
Salspera, Inc. (TKVA) has filed proposed terms for an $85 million U.S. IPO, according to an S-1/A SEC registration statement. The firm is developing a drug candidate for the treatment of pancreatic ...
Salspera has filed for an initial public offering. The biopharmaceutical company aims to trade on the Nasdaq Global Market under the ticker TKVA, according to a filing with the Securities and Exchange ...
Saltikva®, provides patients and oncologists with a novel immunotherapeutic option that has been shown to be highly effective and exceptionally safe. Orally bioavailable Saltikva®, when administered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results